Your AI-Trained Oncology Knowledge Connection!
The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.
The European Medicines Agency has granted marketing authorization to duvelisib for single-agent use in patients with relapsed/refractory chronic lymphocytic leukemia who have previously received at least 2 therapies or those with follicular lymphoma whose disease is refractory to at least 2 previous systemic therapies.
The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.
The addition of toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses in patients with advanced hepatocellular carcinoma, and represents a potential new treatment option for patients in the first line setting.
The FDA has extended the review period for the supplemental new drug application for ruxolitinib as a therapeutic option for adult and pediatric patients aged 12 years and older with steroid-refractory chronic graft-versus-host disease.
In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.
Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.
The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Subsequent systemic therapies were found to impact overall survival outcomes with lenvatinib plus everolimus versus sunitinib in patients with advanced renal cell carcinoma who received treatment in the phase 3 CLEAR trial.
Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.
The addition of olaparib to bevacizumab provided a substantial progression-free survival (PFS) and second PFS benefit over bevacizumab alone in the maintenance treatment of patients with homologous recombination deficiency–positive, newly diagnosed advanced ovarian cancer, regardless of International Federation of Gynecology and Obstetrics disease stage.
The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
The heat shock protein 90 inhibitor pimitespib led to a significant improvement in progression-free survival and prolongation in overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib.
Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.
The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.
The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.
Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.
The 2-year progression free survival achieved with carfilzomib, cyclophosphamide, and dexamethasone consolidation did not prove to be noninferior to up-front autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma, although the margin is small.
The personalized cancer vaccine AV-GBM-1, developed by AIVITA Biomedical Inc., significantly improved progression-free survival over standard of care in patients with newly diagnosed glioblastoma.
Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
The addition of regorafenib to avelumab demonstrated modest anti-tumor responses and survival benefit in patients with heavily pretreated biliary tract cancer.
The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.
Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.
The FDA has approved the expanded use of ravulizumab-cwvz (Ultomiris) to include children aged 1 month and older, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.
